AbbVie (ABBV)
Develops immunology, neuroscience, oncology, and aesthetics products led by Skyrizi and Rinvoq.
$265.01
After hours−0.26 (−0.10%)
At close$265.27(+0.30%)
In millions of USD, except per-share figures
| In millions | Q3 FY23Sep 2023 | Q4 FY23Dec 2023 | Q1 FY24Mar 2024 | Q2 FY24Jun 2024 | Q3 FY24Sep 2024 | Q4 FY24Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 13,927 | 14,301 | 12,310 | 14,462 | 14,460 | 15,102 | 13,343 | 15,423 | 15,776 | 16,618 | 15,002 | 16,990 |
| Cost of revenue | 6,485 | 5,704 | 4,094 | 4,202 | 4,212 | 4,396 | 4,002 | 4,346 | 5,304 | 4,552 | 4,218 | 4,291 |
| Gross profit | 7,442 | 8,597 | 8,216 | 10,260 | 10,248 | 10,706 | 9,341 | 11,077 | 10,472 | 12,066 | 10,784 | 12,699 |
| 5,161 | 5,402 | 5,418 | 6,262 | 6,417 | 12,196 | 5,608 | 6,183 | 8,568 | 6,257 | 6,050 | 6,267 | |
| Research & development | 1,723 | 2,209 | 1,939 | 1,948 | 2,130 | 6,774 | 2,067 | 2,131 | 2,319 | 2,579 | 2,472 | 2,344 |
| Selling, general & administrative | 3,372 | 3,193 | 3,315 | 3,377 | 4,205 | 3,855 | 3,293 | 3,253 | 3,569 | 3,895 | 3,578 | 3,632 |
| Other expenses | 66 | 0 | 164 | 937 | 82 | 1,567 | 248 | 799 | 2,680 | −217 | 0 | 291 |
| Operating income | 2,281 | 3,195 | 2,798 | 3,998 | 3,831 | −1,490 | 3,733 | 4,894 | 1,904 | 5,809 | 4,734 | 6,432 |
| −328 | −1,983 | −1,043 | −1,852 | −1,747 | −779 | −2,072 | −3,340 | −1,190 | −3,141 | −3,695 | −2,154 | |
| Interest income | 157 | 186 | 207 | 220 | 129 | 92 | 73 | 62 | 72 | 59 | 72 | 67 |
| Interest expense | 555 | 564 | 660 | 726 | 720 | 702 | 700 | 740 | 739 | 714 | 717 | 746 |
| Other non-operating income | −227 | 1,419 | 383 | 1,126 | 1,027 | 77 | 1,372 | 2,600 | 451 | 2,427 | 2,978 | −291 |
| Income before tax | 1,953 | 1,212 | 1,755 | 2,146 | 2,084 | −2,269 | 1,661 | 1,554 | 714 | 2,668 | 1,039 | 4,278 |
| Income tax expense | 172 | 388 | 383 | 773 | 520 | −2,246 | 372 | 613 | 526 | 853 | 342 | 662 |
| Net income from continuing operations | 1,781 | 824 | 1,372 | 1,373 | 1,564 | −23 | 1,289 | 941 | 188 | 1,815 | 697 | 3,616 |
| Other adjustments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4 | 0 |
| Net income | 1,778 | 822 | 1,369 | 1,370 | 1,561 | −22 | 1,286 | 938 | 186 | 1,816 | 699 | 3,613 |
| EPS, basic | $1.00 | $0.46 | $0.77 | $0.77 | $0.88 | −$0.02 | $0.72 | $0.53 | $0.10 | $1.02 | $0.39 | $2.04 |
| EPS, diluted | $1.00 | $0.46 | $0.77 | $0.77 | $0.88 | −$0.02 | $0.72 | $0.53 | $0.10 | $1.02 | $0.39 | $2.04 |
| Weighted average shares, basic | 1,767 | 1,766 | 1,769 | 1,769 | 1,769 | 1,769 | 1,768 | 1,772 | 1,772 | 1,774 | 1,774 | 1,771 |
| Weighted average shares, diluted | 1,771 | 1,772 | 1,773 | 1,771 | 1,772 | 1,773 | 1,772 | 1,772 | 1,772 | 1,774 | 1,774 | 1,771 |
| EBITDA | 4,743 | 3,852 | 4,489 | 5,003 | 4,883 | 535 | 4,400 | 4,344 | 3,516 | 5,369 | 3,692 | 8,659 |
| Depreciation & amortization | 2,235 | 2,076 | 2,074 | 2,131 | 2,079 | 2,102 | 2,039 | 2,050 | 2,063 | 1,987 | 1,936 | 1,936 |
| EBIT | 2,508 | 1,776 | 2,415 | 2,872 | 2,804 | −1,567 | 2,361 | 2,294 | 1,453 | 3,382 | 1,756 | 6,723 |